Flagship Pioneering, an American life sciences venture capital company, led a $123m Series C round in Senda Biosciences, a company that is harnessing nature to program targeted, potent, and tunable medicines, with participation from Samsung Life Science Fund, Qatar Investment Authority, Bluwave Capital, Stage 1 Ventures, Alexandria Venture Investments, Longevity Vision Fund, Mayo Clinic, Partners Investment, and State of Michigan Retirement System. "Senda is pioneering the development of comprehensively programmable medicines with the potential to reach previously inaccessible cells, tissues, and organs. We believe our approach could transform the lives of patients in need of novel treatments, and so we're delighted to have attracted support from investors who recognize this potential and its significance," Guillaume Pfefer, Senda Biosciences CEO.